ABSTRACT Background. Sequencing therapy for patients with periampullary malignancy is controversial. Clinical trial data report high rates of adjuvant therapy completion, though contemporary, real-world rates remain incomplete. We sought to identify patients who failed to receive adjuvant therapy and those at risk for early recurrence (ER) who might benefit most from neoadjuvant therapy (NT). Methods. We retrospectively reviewed medical records of 201 patients who underwent pancreaticoduodenectomy for periampullary malignancies between 1999 and 2015; patients receiving NT were excluded. Univariate and multivariate analyses were performed to identify predictors of failure to receive adjuvant therapy and ER (within 6 months) as the primary end points. Results. The median age at the time of surgery was 65.5 years (interquartile range 57-74 years). The majority of tumors were pancreatic ductal adenocarcinoma (76.6 %), and 71.6 % of patients received adjuvant therapy after resection. Univariate predictors of failure to undergo adjuvant therapy were advanced age, age-adjusted Charlson comorbidity index, operative transfusion, reoperation, length of stay, and 30-to 90-day readmissions (all p \ 0.05). Advanced age, specifically among patients [70 years, persisted as a significant preoperative predictor on multivariate analysis (p \ 0.01). Patients who failed to receive adjuvant therapy and/or developed ER had significantly worse overall survival rates compared to all other patients (27.8 vs. 9.7 months; p \ 0.01).
length of stay, and 30-to 90-day readmissions (all p \ 0.05). Advanced age, specifically among patients [70 years, persisted as a significant preoperative predictor on multivariate analysis (p \ 0.01). Patients who failed to receive adjuvant therapy and/or developed ER had significantly worse overall survival rates compared to all other patients (27.8 vs. 9.7 months; p \ 0.01).
Conclusions. Approximately one-third of surgery-first patients undergoing pancreaticoduodenectomy at our institution did not receive adjuvant therapy and/or demonstrated ER. This substantial subset of patients may particularly benefit from NT, ensuring completion of multimodal therapy and/or avoiding futile surgical intervention.
The incidence of periampullary neoplasms has risen in the past decade. Pancreatic cancer, the most common type, is projected to be responsible for 53,070 new diagnoses and 41,780 deaths in 2016. 1 The closely matched incidence and mortality of this disease are reflective of its aggressive nature.
Surgical resection-pancreaticoduodenectomy (PD)-remains the only opportunity for a cure. However, given pancreatic cancer's biology, with a 5-year survival of 15-20 % among patients with resectable disease, surgical intervention alone remains suboptimal. 2, 3 Randomized prospective trials have validated adjuvant therapy as an important treatment modality that improves overall survival (OS), though only 60-80 % of patients randomized to receipt of adjuvant therapy complete their treatment course. [4] [5] [6] [7] [8] [9] These rates are problematic, given that patients enrolled onto clinical trials are highly selected. Outside of clinical trials, postoperative complications are primarily implicated in many patients not receiving adjuvant therapy, negatively affecting their OS. [10] [11] [12] Similarly, patients who develop early disease recurrence also exhibit worse OS rates [13] [14] [15] Disease-free recurrence is largely dictated by tumor stage, lymph node involvement, and lymph node ratio, and these pathologic factors limit long-term survival to a select minority of patients with early-stage disease. [16] [17] [18] [19] [20] Given these limitations of the traditional surgery-first approach, neoadjuvant therapy (NT) is an attractive option. Not only does NT ensure completion of multimodal therapy, but it also allows for improved patient selection, as patients at heightened risk for early recurrence (ER) can be spared a major operation. Outcomes and risk factors on both omission of adjuvant therapy (OAT) and ER in the same population is lacking. We sought to determine which preoperative clinical factors may be used to identify patients vulnerable to OAT and/or ER in order to identify patients who may particularly benefit most from NT.
METHODS

Study Design and Data Collection
Using an institutional review board-approved pancreas database, we identified 234 patients who underwent PD with curative intent for resectable periampullary malignancies between 1999 and 2015 at the University of Cincinnati Medical Center. Patients sequenced with NT were excluded. Complete postoperative data were available for 201 patients, which comprised the final study population. A retrospective review of medical records incorporated perioperative data.
Patient comorbidity was stratified by the age-adjusted Charlson comorbidity index (CACI). 21 The comorbidity score was calculated at the time of periampullary cancer diagnosis based on clinical history. Age adjustment was factored with the addition of one point per decade past the fourth decade of life.
Postoperative complications were classified according to the Clavien-Dindo system. 22 Receipt of adjuvant therapy, recidivism, recurrence, and death were catalogued. OAT was defined as never receiving systemic therapy in the absence of radiographic disease. ER was defined as radiographic evidence of local progression or distant metastases within 6 months of resection. Patients who recurred before 12 weeks were excluded from analysis involving receipt of adjuvant therapy. OS was calculated from the date of surgery to the last documented follow-up or death.
Statistical Methods
Continuous variables were compared using the KruskalWallis H test and expressed as median (interquartile range), and Fisher's exact test were used to compare categorical variables. Predictor variables were chosen based on their statistical significance on univariate analysis (p B 0.10), or if deemed to be clinically significant. Multivariate analyses were performed with continuous and categorical variables as predictors of OAT and ER. Relative risks were expressed as odds ratios (OR) with a 95 % confidence interval (CI). Survival analysis was calculated using Kaplan-Meier curves and compared using Wilcoxon log-rank tests. An association was considered statistically significant if p \ 0.05. All data analyses were performed by SAS 9.3 software (SAS Institute, Cary, NC).
RESULTS
In the overall cohort, the median age at the time of surgery was 65.5 years (interquartile range 58.0-74.0 years). The majority (76.6 %) of tumors were pancreatic adenocarcinoma, and 71.6 % of patients received adjuvant therapy after resection. Patients with OAT were more likely to be older (74 vs. 63 years, p \ 0.001), have a higher body-mass index (28 vs. 25 kg/m 2 , p = 0.034), have higher CACI scores (5 vs. 3, p \ 0.001), have lower preoperative albumin levels (3.7 vs. 3.9 g/dL, p = 0.009), and have higher carbohydrate antigen 19-9 levels (178.5 vs. 76.0 U/mL, p = 0.038). Patients not receiving adjuvant therapy also had adverse perioperative characteristics, with increased severe complications (42.1 vs. 14.5 % grade III/ IV, p \ 0.001), length of stay (13 vs. 9 days, p \ 0.001), and 30-to 90-day readmission rates (28.1 vs. 11.1 %, p = 0.005). Additional demographics and clinicopathologic characteristics are depicted in Table 1 .
On univariate analysis, age ([70 vs. \60, OR, 10.42; 95 % CI, 3.79-28.57; p \ 0.001), CACI C6 (OR, 3.46; 95 % CI, 1.69-7.04; p \ 0.001), and preoperative albumin level \3.4 g/dL (OR, 2.36; 95 % CI, 1.05-5.29; p = 0.036) were associated with an increased likelihood of OAT. After adjustment on multivariate analyses, age was the only preoperative factor that was a persistent predictor of OAT (Table 2) Of the 144 patients who received adjuvant therapy, 44 % (n = 64) of patients had a delayed initiation of therapy past 8 weeks from the date of surgery. On univariate analysis, age, especially those older than 70 years (OR, 3.43; 95 % CI, 1.40-8.42, p \ 0.01), increased the likelihood of a delayed start in adjuvant therapy after resection. This effect was maintained on multivariate analysis, as patients in their seventh decade and older were five times more likely to experience delayed adjuvant therapy (OR, 5.53; 95 % CI, 1.18-25.8; p = 0.03). Amongst patients who received adjuvant therapy, experiencing a delay in treatment did not affect OS (data not shown). The vast majority of patients who received adjuvant therapy initiated therapy at or before 12 weeks from the date of surgery (n = 118; 81.9 %). The median survival of patients who received adjuvant therapy 8 weeks from the date of surgery was 21.0 months, compared to 20.4 months for patients who initiated therapy between 8 to 12 weeks after surgery (p = 0.995).
ER was detected in 15.9 % of patients (n = 32), and patients older than 70 years (OR, 1.93; 95 % CI, 3.80-8.43; p = 0.04) were more likely to have ER on univariate analysis (Table 3 ). This effect was maintained on multivariate analysis in this age group (OR, 2.17; 95 % CI, 1.04-4.76; p = 0.048). In addition, having a preoperative total bilirubin level greater than 10 mg/dL increased the likelihood of ER on both univariate (OR, 4.32; 95 % CI, 1.32-14.12; p = 0.02) and multivariate analysis (OR, 5.18; 95 % CI, 1.47-18.2; p = 0.01). Patients who experienced disease recurrence at, or before, 6 months had worse median OS compared to patients without ER (OS, 9.1 vs. 27.2 months, p \ 0.001; Fig. 1b) . These results are consistent among the pancreatic cancer cohort, with patients who had ER experiencing worsened median OS compared to patients who did not (8.1 vs. 26.3 months, p \ 0.001; Supplementary Fig. B) .
Nearly half of the study population, 42.3 % (n = 85) either developed ER and/or did not receive adjuvant Fig. 1c ). This was consistent among the subgroup of patients with pancreatic cancer, resulting in worse OS among those with ER, OAT, or both compared to patients who did not experience either events (9.5 vs. 27.5 months, p \ 0.001; Supplementary  Fig. C) . On multivariate analysis of preoperative factors associated with OAT, ER, and ER/OAT, the interaction term of age and CACI was not significant.
DISCUSSION
We have demonstrated that for patients undergoing PD for periampullary malignancies, advanced age significantly increases the chances of OAT, ER, or both. This is especially pronounced among patients older than 70 years, a population underrepresented in clinical trials. 23 The resultant survival disadvantage, among patients with periampullary malignancies and among patients with pancreatic cancers alone, compared to patients who did not experience these adverse postoperative events, is substantial. Thus, we can identify a sizeable cohort-over 40 % of our patient population-who may substantially benefit from a neoadjuvant approach.
Surgery followed by adjuvant chemotherapy has traditionally been the standard paradigm for resectable periampullary malignancies. 24 In our study, compared to patients who received adjuvant therapy, patients with OAT experienced more adverse perioperative events. These findings support previously published data, in which postoperative complications were associated with OAT. 10 Although postoperative mortality has improved since the 1990s, complication rates have not changed. 25 , 26 As a result, a significant proportion of patients do not go on to receive adjuvant therapy, whether on a clinical trial or receiving care off protocol. An analysis of the American College of Surgeons National Surgical Quality Improvement Program and the National Cancer Data Base reported that only 58 % of patients after resection received adjuvant therapy. 10 Even advancements in surgical technique, such as the introduction of minimally invasive PD, have not BMI body mass index, CACI age-adjusted Charlson comorbidity index, CA19-9 carbohydrate antigen 19-9, PDA pancreatic ductal adenocarcinoma, EBL estimated blood loss resulted in improvement in adjuvant therapy rates. 27 Furthermore, a significant percentage of patients demonstrate ER, negating any benefits of surgical intervention. An opportunity exists to identify, preoperatively, subpopulations of patients in whom a neoadjuvant sequence may spare them the morbidity of PD.
Given the poor rate of adjuvant therapy utilization, and evidence that patients who receive multimodal therapy have improved OS, surgeons should be open to the potential benefits of NT. Retrospective studies have demonstrated the feasibility of NT in patients with resectable disease, especially among elderly patients. 28 , 29 Miura et al. reported comparable NT completion rates between patients older than 75 years and patients younger than 75 years, with no increase in perioperative complications. 30 In addition, NT is cost-effective and allows to ''selectin'' patients with localized disease whom would benefit most from resection, and avoid the morbidity of PD in patients who will demonstrate radiographic evidence of metastatic disease during the course of NT [31] [32] [33] [34] Currently, we lack the tools to accurately predict which patients are at risk for OAT and ER, and would therefore derive benefit from multimodality treatment upfront with NT; this is the strength of our study.
Our goal was to identify preoperative factors predicting OAT, ER, or both, that are associated with worse OS (all p \ 0.01). On univariate analysis, age, CACI, and preoperative albumin were associated with OAT, while age and preoperative total bilirubin [10 mg/dL were associated with early 6-month recurrence. Age [70 years persisted on multivariate analysis for both postresection metrics, though there are conflicting reports on the perioperative outcomes of elderly patients after PD [35] [36] [37] [38] Age is often intimately associated with a patient's performance status, affecting a clinician and patient's decision for administration of adjuvant therapy. Receipt of adjuvant therapy among elderly patients is important, having demonstrated a protective effect on 2-year survival. 39 In addition to age, a total bilirubin [10 mg/dL increased the likelihood of ER. This may reflect advanced disease, and may be considered a surrogate for patients with worse tumor biology. In addition, hyperbilirubinemia may also affect the performance status of the patient before and after surgery, influencing recovery and completion of adjuvant therapy. Previous studies have implicated jaundice as an independent prognostic factor of early mortality in pancreatic ductal adenocarcinoma. 40, 41 It is of interest that CACI did not achieve significance along with age on multivariate analysis. In addition, we found no significant interaction between age and CACI on multivariate analysis. This may be attributed to the comparable baseline comorbidities in our study population, when age is not factored in. Dias-Santos et al. reported that CACI is a useful tool in predicting length of stay, postoperative complications, and 1-year mortality. 42 However, their findings on CACI cannot be extrapolated to OAT, as their study included patients who received NT, and who underwent distal pancreatectomy and total pancreatectomy in addition to PD. Furthermore, Dale et al. report the use of preoperative geriatric assessment to predict postoperative outcomes and identify older patients at risk for complications. 43 In their study, patients with ''exhaustion'' within the Fried's model of frailty were fourfold more likely to experience a major complication. Although this study primarily measured complications and 30-day readmission, it would be of interest to see if preoperative assessment of biologic age can predict receipt and completion rate adjuvant therapy.
Even less is known about the effect of timeliness to adjuvant therapy. On our univariate and multivariate analysis, patients over 70 were more likely to experience a delay in therapy. However, we found that a delay in adjuvant therapy did not affect OS compared to patients who received their therapy before that cutoff point. This is comparable to the most recent follow-up of the ESPAC-3 treatment arm population, in which completion of chemotherapy, rather than time to initiation, was an independent prognostic factor in terms of disease free and OS. 44 Although no convincing data exist on the use of NT for nonpancreatic periampullary cancers, the ESPAC-3 trial validated the role of multimodal therapy in these malignancies. Our study was inclusive of nonpancreatic periampullary cancers in order to comprehensively address the population of patients at risk for OAT. The findings of Valle et al. reinforce the concept that patients should not initiate adjuvant therapy until they have recovered sufficiently, and those who experience a prolonged postoperative recovery should not be discouraged from multimodal therapy. 44 Yet these recent finding alone cannot answer for the significant portion of surgery-first patients who do not receive adjuvant therapy at all, as reasons are multifactorial.
The limitations of this study are related to its retrospective nature. First, patients with incomplete data on receipt of adjuvant therapy were omitted from analysis (n = 33). Second, we were unable to control for the adjuvant therapy regimen, duration, and completion during the time period of this study. Third, some patients with ER may not have been captured due to incomplete follow-up; as a tertiary care referral center, patients who originate from outside our geographic region may choose to receive nonoperative care outside of our facility. Last, we would expect that with larger study numbers, more univariate results would have persistent statistical significance on multivariate analyses, strengthening our results.
CONCLUSIONS
Our findings indicate that elderly patients, especially past their seventh decade, are most at risk for OAT and ER after PD. This results in a striking survival disadvantage. We submit that elderly patients over the age of 70 years are at elevated risk for OAT and/or ER; they should be considered for NT, rather than a surgery-first approach, based on the associated benefit of completion of multimodal therapy and improved survival.
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